Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. KTTA
KTTA logo

KTTA Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Pasithea Therapeutics Corp (KTTA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
0.780
1 Day change
-1.76%
52 Week Range
3.790
Analysis Updated At
2026/05/15
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

KTTA is not a good buy right now for a beginner long-term investor with $50,000-$100,000. The stock is showing only a modest pre-market pop, but there is no strong proprietary buy signal, no supportive news catalyst, neutral insider/hedge fund activity, and weak forward trend expectations. For an impatient buyer, this is not a clear entry. Best current stance: hold and wait for a stronger setup.

Technical Analysis

KTTA is in a mixed/neutral technical position. Pre-market price is 0.837, up 5.39%, but the broader signal is not confirming strength. MACD histogram is slightly positive at 0.00417 and positively contracting, which suggests momentum is improving but not decisively. RSI_6 at 53.553 is neutral, so the stock is neither oversold nor strongly trending. Moving averages are converging, pointing to a possible inflection but not a confirmed breakout. Key levels: pivot 0.823, resistance 0.928/0.992, support 0.719/0.655. The near-term pattern forecast is weak, with expected moves of -0.06% next day, -2.32% next week, and -7.15% next month, which argues against an immediate buy.

Positive Catalysts

  • ["Pre-market price is up 5.39%, showing short-term buyer interest.", "MACD histogram is above zero, indicating slight improving momentum.", "Price is trading above the pivot level at 0.823.", "No recent insider selling trend and hedge funds are neutral rather than negative."]

Neutral/Negative Catalysts

  • ["No news in the recent week, so there is no event-driven catalyst.", "AI Stock Picker: no signal on given stock today.", "SwingMax: no signal on given stock recently.", "Insiders are neutral and hedge funds are neutral, with no strong accumulation trend.", "Similar candlestick pattern analysis points to weaker performance over the next week and month.", "Pre-market strength is not backed by a confirmed technical breakout.", "No recent congress trading data available.", "No valuation data and financial snapshot is unavailable, limiting fundamental support."]

Financial Performance

No usable latest-quarter financial snapshot was available because of a data error, so there is no reliable quarter-by-quarter revenue or earnings growth assessment to support a long-term buy case.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so there is no evidence of a positive Wall Street upgrade trend. Based on the available data, Wall Street appears neutral at best: there is no clear pro-buy consensus, and the lack of news, signals, and financial visibility makes the pros view weak. The main pro is the short-term pre-market bounce; the main con is the absence of confirming fundamentals, catalysts, or strong rating momentum.

Wall Street analysts forecast KTTA stock price to rise
1 Analyst Rating
Wall Street analysts forecast KTTA stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.794
sliders
Low
3
Averages
3
High
3
Current: 0.794
sliders
Low
3
Averages
3
High
3
H.C. Wainwright
Sara Nik
Buy
initiated
$3
AI Analysis
2025-12-08
Reason
H.C. Wainwright
Sara Nik
Price Target
$3
AI Analysis
2025-12-08
initiated
Buy
Reason
H.C. Wainwright analyst Sara Nik initiated coverage of Pasithea Therapeutics with a Buy rating and $3 price target. The firm says the company has a next-generation MEK inhibitor "set to tackle both orphan and oncology markets." The analyst views Pasithea's pipeline as being the "best-in-class comprehensive attack" on the MAPK pathways, potentially yielding access to a $20B potential market in multiple indications.

People Also Watch